Products
Lifastuzumab Vedotin Biosimilar Antibody-Drug Conjugate (SLC34A2) for Research
Pre-made Lifastuzumab Vedotin benchmark antibody (Whole mAb ADC, anti-SLC34A2 therapeutic antibody, Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lifastuzumab vedotin (INN;[1] development code DNIB6A) is a monoclonal antibody designed for the treatment of cancer.[2]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-893-1mg | 1mg | 4635 |
| GMP-Bios-INN-893-10mg | 10mg | |
| GMP-Bios-INN-893-100mg | 100mg | |
| GMP-Bios-INN-893-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lifastuzumab Vedotin Biosimilar, Whole Mab Adc, Anti-Slc34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody Drug Conjugate |
| INN Name | Lifastuzumab Vedotin |
| Target | SLC34A2 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - SLC34A2
1. Protein Sodium-dependent phosphate transport protein 2B
2. Gene SLC34A2
3. Organism Homo sapiens (Human)
Function
May be involved in actively transporting phosphate into cells via Na+ cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the synthesis of surfactant in lungs' alveoli.
pH dependence
Optimum pH is 6.6.
